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The treatment of advanced prostate cancer has been
transformed by novel antiandrogen therapies such
as enzalutamide. Here, we identify induction of
glucocorticoid receptor (GR) expression as a com-
mon feature of drug-resistant tumors in a creden-
tialed preclinical model, a finding also confirmed in
patient samples. GR substituted for the androgen
receptor (AR) to activate a similar but distinguishable
set of target genes and was necessary for mainte-
nance of the resistant phenotype. The GR agonist
dexamethasone was sufficient to confer enzaluta-
mide resistance, whereas a GR antagonist restored
sensitivity. Acute AR inhibition resulted in GR upre-
gulation in a subset of prostate cancer cells due to
relief of AR-mediated feedback repression of GR
expression. These findings establish a mechanism
of escape from AR blockade through expansion of
cells primed to drive AR target genes via an alterna-
tive nuclear receptor upon drug exposure.INTRODUCTION
Recently approved drugs that target androgen receptor (AR)
signaling such as abiraterone and enzalutamide have rapidly
become standard therapies for advanced-stage prostate cancer
(Scher et al., 2012; de Bono et al., 2011). Despite their success,
sustained response with these agents is limited by acquired
resistance, which typically develops within 6–12 months. Clin-
ical success of kinase inhibitors in other tumors such as mela-
noma, lung cancer, leukemia, and sarcoma is similarly transient
(Sawyers et al., 2002; Chapman et al., 2011; Demetri et al., 2002;
Maemondo et al., 2010), resulting in numerous efforts to define
mechanisms of acquired resistance. One strategy that has
proven particularly useful is prolonged treatment of drug-sensi-tive preclinical models to derive drug-resistant sublines, followed
by genome-wide profiling studies to ascertain differences that
may play a causal role in conferring drug resistance. A common
mechanism that has emerged from these kinase inhibitor studies
is reactivation of the signaling pathway targeted by the drug,
directly by mutation of the kinase target or indirectly by bypass-
ing pathway inhibitor blockade through amplification of an alter-
native kinase (Glickman and Sawyers, 2012). Both scenarios
have been validated in clinical specimens and are guiding efforts
to discover next-generation inhibitors and to develop rational
drug combinations.
Clinically relevant mechanisms of resistance to hormone ther-
apy in prostate cancer have also been elucidated using preclin-
ical models. Hormone therapy, through the use of drugs that
lower serum testosterone or competitively block the binding of
androgens to AR, has been the mainstay of treatment for meta-
static prostate cancer for decades but is not curative. The late
stage of disease, which is refractory to hormone therapy, is
termed castration-resistant prostate cancer (CRPC). We previ-
ously examined the molecular basis of progression to CRPC in
mouse models and discovered that increased AR expression
was the primary mechanism (Chen et al., 2004). We then used
this observation to screen for antiandrogens that restore AR
inhibition in the setting of increased AR levels. These efforts
yielded three second-generation antiandrogens: enzalutamide,
ARN-509, and RD162 (Tran et al., 2009; Clegg et al., 2012). En-
zalutamide and ARN-509 were further developed for clinical
use, culminating in US Food and Drug Administration (FDA)
approval of enzalutamide in 2012 based on increased survival
(Scher et al., 2012).
Now, with widespread use, resistance to enzalutamide is a
major clinical problem. We and others have recently identified
an AR point mutation as one resistancemechanism by derivation
of drug-resistant sublines following prolonged exposure to
enzalutamide or ARN-509 (Balbas et al., 2013; Joseph et al.,
2013; Korpal et al., 2013). This ARmutation has also been recov-
ered from patients with resistance to ARN-509 but only in a
minority of cases (Joseph et al., 2013). Here, we define aCell 155, 1309–1322, December 5, 2013 ª2013 Elsevier Inc. 1309
Figure 1. GR mRNA and Protein Are Ex-
pressed in Resistant Tissues
(A) Most differentially expressed genes in a pilot
cohort of LnCaP/AR xenograft tumors with
acquired resistance to ARN-509 (n = 6) or RD162
(n = 9) compared to control (n = 3) determined
by microarray (Affymetrix Ex1.0). Mice with resis-
tant tissues were continued on drug treatment
through time of harvest. In vitro androgen-induced
or -repressed genes are annotated (see also Table
S1B).
(B) Mean tumor volumes ± SEM of LnCaP/AR
xenografts in validation cohort. Days tumors that
were harvested are annotated on x axis (long hash
mark).
(C) RT-qPCR analysis of GR and AR mRNA
expression in a validation cohort of LnCaP/AR
xenograft tumors from mice treated with vehicle
(control, n = 10), 4 days of antiandrogen (n = 8), or
with acquired resistance to 10 mg/kg enzaluta-
mide (n = 8) or 10 mg/kg ARN-509 (n = 8). See also
Table S1B.
(D) Western blot analysis of GR and AR protein
expression in a subset of tissues also analyzed
in (C). Control (n = 6), 4 day (n = 5), and resistant
(n = 13). Resistant samples were loaded for protein
analysis from highest to lowest GR levels based
on corresponding mRNA analysis (see also Table
S1C).
(E) Intracellular GR flow cytometric analysis of
LnCaP/AR, CS1, and LREX0, cells passaged
in vitro under standard passage conditions (see
Experimental Procedures).
See also Figure S1.potentially more prevalent mechanism of resistance by which
tumors bypass AR blockade through upregulation of the gluco-
corticoid receptor (GR).
RESULTS
GR Is Expressed in Antiandrogen-Resistant Tumors
We previously showed that LNCaP/AR xenograft tumors regress
during the first 28 days of treatment with ARN-509 (Clegg et al.,
2012), enzalutamide, or RD162 (Tran et al., 2009). In a pilot study
to explore mechanisms of acquired resistance to these drugs,
we treated mice continually and harvested tumors after progres-
sion (mean 163 days, Table S1A available online). Tissue from 15
resistant tumors obtained from long-term antiandrogen-treated
mice (n = 6 ARN-509, n = 9 RD162) and from 3 control tumors1310 Cell 155, 1309–1322, December 5, 2013 ª2013 Elsevier Inc.from vehicle-treated mice were analyzed
by expression array. Aggregated data
from resistant and control tumors in this
pilot cohort were compared to identify
expression changes commonly associ-
ated with resistance (Figure 1A). Among
the most upregulated genes in the resis-
tant tumors was the GR (gene symbol
NR3C1), which shares overlapping target
specificity with AR (Mangelsdorf et al.,1995). Of note, several of themost differentially expressed genes
were known androgen-regulated genes (confirmed by transcrip-
tome analysis of short-term dihydrotestosterone (DHT)-treated
LnCaP/AR cells in vitro [Table S1B]), but they were altered in
directions that did not reflect restored AR signaling. On the one
hand, SGK1 (Serum Glucocorticoid Induced Kinase 1), a known
AR- and GR-induced target gene, was among the most up-
regulated genes, but several other androgen-induced genes
(PMEPA1, SNAI2, KCNN2, LONRF1, and SPOCK1) were among
the most repressed. Conversely, several androgen-repressed
genes (UGT2B15, PMP22, CAMK2N1, and UGT2B17) were
among the most upregulated (Figure 1A). These findings indi-
cated that resistance in this model system is unlikely to be
mediated by simple restoration of AR activity and raised the pos-
sibility that GR may play a role.
Figure 2. GR Is Necessary for Resistance in
the LREX0 Xenograft Model
(A) Mean tumor volume ± SEM of LREX0 (n = 20) or
LnCaP/AR (n = 14) cells in castrate mice treated
with 10 mg/kg enzalutamide.
(B) Mean tumor volumes ± SEM of CS1 in castrate
mice treated with vehicle (n = 10) or 10 mg/kg
ARN-509 (n = 10).
(C) GR IHC of enzalutamide (10 mg/kg)-treated
LREX0 tumors and vehicle-treated LnCaP/AR
xenograft tissues. Blue arrow, endothelial/stromal
cells; black arrow, epithelial cell.
(D) Mean tumor volumes ± SEM of LREX0 xeno-
grafts in 10 mg/kg enzalutamide-treated castrate
mice after infection with a nontargeting (n = 14) or
GR-targeting (n = 12) hairpin. Comparison is by
Mann-Whitney test.
(E) Tumor growth curve of CS1 in castrate mice
after infection with the nontargeting (n = 20) or GR-
targeting (n = 20) hairpin.
(F) Western blot analysis of GR expression in
LREX0 cells prior to implantation and of available
tissues from (D) at day 49.
See also Figure S1.To explore this question further, we generated an
independent set of drug-resistant tumors (the validation cohort),
focusing on the two second-generation antiandrogens in
clinical use, enzalutamide and ARN-509 (Figure 1B). GR
messenger RNA (mRNA) levels in resistant tumors were
substantially higher compared to control (median 26.9-fold
increase) or 4 day treated tumors (Figure 1C). Of the tissues
analyzed by RT-qPCR, most were also analyzed for GR ex-
pression by western blot, based on availability of protein lysates
(control, n = 6; 4 day, n = 5; resistant, n = 13). No GR was de-
tected in control samples, minimal expression was noted in
4 day treated samples, and substantial expression was found
in most resistant tumors in a pattern that tended to correlate
with GR mRNA levels (Figure 1D). There was no correlation
betweenGR expression and the specific antiandrogen treatment
used (Table S1C). In contrast to GR, AR RNA or proteins
levels were not consistently different across the treatment
groups (Figures 1C and 1D).Cell 155, 1309–1322, DTo explore AR and GR signaling in
more detail, we established cells lines
from control and drug-resistant tumors
by adaptation to growth in vitro. LREX0
(LnCaP/AR Resistant to Enzalutamide
Xenograft derived) was derived from an
enzalutamide-resistant tumor with high
GR expression, and CS1 was derived
from a vehicle-treated tumor. We also
developed a flow cytometry-based assay
to measure GR expression on a cell-by-
cell basis. In both LNCaP/AR and CS1,
most cells showed no evidence of GR
expression, with the exception of a small
subpopulation (black arrow, discussed
later) (Figure 1E). In contrast, essentiallyall LREX0 cells expressed GR. Intracellular AR staining confirmed
that AR levels in LREX0 did not notably differ from control cells
(Figure S1A).
LREX0 Tumors Are Dependent on GR for Enzalutamide-
Resistant Growth
Having established the LREX0 model as representative of high
GR expression, we next confirmed that these cells maintain a
resistant phenotype in vivo. LREX0 or control cells were injected
into castrated mice that were then immediately initiated on anti-
androgen treatment. LREX0 showed robust growth, whereas
LNCaP/AR or CS1 lines were unable to establish tumors in the
presence of antiandrogen (Figures 2A and 2B). Strong expres-
sion of GR was confirmed in multiple LREX0 xenograft tumors
by western blot and by IHC (Figures S2 and S1B). As expected,
untreated LNCaP/AR tumors were negative for GR expression
with the exception of rare GR-positive cells (Figure 2C). Although
many of these GR-positive cells had morphologic features ofecember 5, 2013 ª2013 Elsevier Inc. 1311
stromal or endothelial cells (blue arrows), some appeared epithe-
lial (black arrow), which is consistent with the flow cytometry
analysis (Figure 1E, black arrows).
To determine whether GR expression is required to maintain
the drug-resistant phenotype, LREX0 cells were infected with a
small hairpin RNA (shRNA)-targeting GR (shGR), and stable
knockdown of GR protein was confirmed (Figure 2F). Tumor
growth of shGR-infected LREX0 cells was significantly delayed
relative to nontargeted (shNT)-infected cells in castrated mice
treated with enzalutamide (Figure 2D). In contrast, shGR had
no impact on the growth of GR-negative CS1 xenografts, dimin-
ishing the possibility of an off-target effect (Figure 2E). Of note,
shGR LREX0 xenografts harvested on day 49 showed decreased
GR protein knockdown compared to the preimplantation levels,
which is indicative of selective pressure against GR silencing in
the setting of enzalutamide treatment (Figure 2F). These findings
provide direct evidence that GR drives enzalutamide resistance
in vivo.
GR Expression Is Associated with Clinical Resistance to
Enzalutamide
To determine whether GR expression is a feature of clinical
antiandrogen resistance, we evaluated GR expression in bone
metastases from patients receiving enzalutamide. Bone marrow
samples were obtained prior to enzalutamide treatment (base-
line) and again after 8 weeks of treatment, as previously reported
in a cohort of abiraterone-treated patients (Efstathiou et al.,
2012). Using a GR immunohistochemistry (IHC) assay optimized
for use in bone marrow samples, we quantified the percentage
of GR-positive tumor cells and dichotomized the data based
on clinical response. Patients who continued to benefit from
therapy for greater than 6 months were defined as good re-
sponders, whereas those in whom therapy was discontinued
earlier than 6 months due to a lack of clinical benefit were clas-
sified as poor responders (Figure 3A). Consistent with the desig-
nation of good versus poor clinical response based on treatment
status at 6 months, 11 of 13 good responders but only 1 of 14
poor responders had a maximal PSA decline greater than 50%
(Figure 3B). Akin to the findings in the preclinical model, GR
positivity at baseline was low—3% of tumor cells in good
responders and 8% in poor responders. Of note, 3 of 22 tumors
had evidence of high GR expression at baseline (R20% of tumor
cells), and all three had a poor clinical response (Figures 3C and
3D). At 8 weeks, the mean percentage of GR-positive cells was
higher than baseline levels in both response groups but was
more significantly elevated in poor responders (29% versus
8%, p = 0.009). In addition, the percentage of GR-positive cells
at 8 weeks was significantly higher in poor compared to good
responders (29% versus 10%, p = 0.02) (Figures 3C and 3D),
and similar results were obtained when the analysis was limited
to patients from whom matched baseline and 8 week samples
were available for analysis (Figure 3E). Furthermore, when GR
IHC data were dichotomized based on PSA decline instead
of clinical response, GR induction was also associated with
a limited PSA decline (Figure S2). These findings establish a
correlation between GR expression and clinical response to
enzalutamide and raise the possibility that AR inhibition may
induce GR expression in some patients. The fact that poor1312 Cell 155, 1309–1322, December 5, 2013 ª2013 Elsevier Inc.PSA decline also correlates with GR expression raises the ques-
tion of whether transcriptional regulation of a canonical AR target
gene may be regulated by GR.
GR Expressing Drug-Resistant Tumors Show Uneven
Restoration of AR Target Genes
Having implicated GR as a potential mediator of antiandrogen
resistance, we next asked whether restored AR pathway activity
also plays a role by comparing the mRNA transcript levels of 74
direct AR target genes in control, 4 day, and resistant tumors
from the validation cohort (Figure S3), as well as eight LREX0
tumors (Figure 4A) (see Experimental Procedures and Table S2
for details on gene selection).
Consistent with the data generated in the pilot cohort (Fig-
ure 1A), some AR target genes in resistant tissues showed
elevated levels relative to control (SGK1 and STK39), whereas
other genes (NDRG1, TIPARP, and PMEPA1) showed no evi-
dence of restored expression.
To examine restoration of AR signaling across the entire set
of 74 target genes, we calculated a fractional restoration value
using log 2 transformed expression values and the equation
(resistant – 4 day)/(control – 4 day). With this approach, a gene
whose expression in resistant tissue equals the expression in
control tumors calculates as 1, whereas a gene whose expres-
sion in resistance equals its expression after 4 days of anti-
androgen treatment equals 0. (Values greater than one indicate
hyperrestoration in resistance relative to control, and values
below zero suggest further inhibition as compared to acute treat-
ment.) These data confirmed that the pattern of restoration
varied gene by gene, but this pattern was consistent in LREX0
xenografts and in the validation cohort tumors (Pearson r 0.64,
p = 7.54 3 1010; Figure 4B). This finding is most consistent
with a model in which AR remains inhibited in drug-resistant tu-
mors, but expression of certain AR target genes is restored by an
alternative transcription factor, possibly GR. The fact that resto-
ration values were somewhat higher in the LREX0 analysis corre-
lates with higher GR expression in these tumors (Figure 4C).
GR Drives Expression of AR Target Genes in Resistant
Tissues
To determine whether GR can drive expression of this subset of
AR target genes, we compared, in vitro, DHT-induced (AR) and
dexamethasone (Dex)-induced (GR) expression of seven AR
targets that represent the spectrum of restoration noted in the
in vivo analysis, as well as PSA (Figure 4D). All eight genes
were regulated by DHT as expected, and this regulation was
blocked by enzalutamide. Thus, AR signaling remains intact
and can be inhibited by antiandrogens in these drug-resistant
cells, making an AR-dependent mechanism of drug resistance
less likely.
In contrast to DHT, the effect of Dex on these same target
genes was variable but closely matched the pattern observed
in drug-resistant xenografts. For example, Dex strongly induced
SGK1 and STK39 but did not induce TIPARP, NDRG1, and
PMEPA1. Of note, KLK3 (PSA) was comparably induced by
either DHT or Dex, providing evidence that persistent PSA
expression in patients responding poorly to enzalutamide could
be driven by GR. As expected, enzalutamide did not notably
Figure 3. GR Induction in Disseminated TumorCells Is Associatedwith Poor Clinical Response to Enzalutamide andPersistence of Prostate-
Specific Antigen
(A) Schematic of sample acquisition timeline and response groups.
(B) Number of good or poor responders who achieved prostate-specific antigen (PSA) decline greater than 50%.
(C) Examples of GR IHC images from matched samples at baseline and 8 weeks.
(D and E) (D) Percent GR-positive epithelial cells in all tissue available at 0 and 8weeks or (E) matched samples obtained from the same patient at 0 and 8 weeks ±
SEM. Comparisons are by Mann-Whitney test.
See also Figure S2.affect Dex activity. To confirm that this pattern of GR-dependent
gene expression is not unique to LREX0 cells, we introduced
a GR-expressing retrovirus into parental LNCaP/AR cells and
observed a similar pattern of DHT- versus Dex-induced geneexpression (Figures S4A and S4B). To be sure that the effects
of Dex in these models are mediated through GR, we cotreated
cells with a previously described competitive GR antagonist
that lacks AR binding called compound 15 (Wang et al., 2006).Cell 155, 1309–1322, December 5, 2013 ª2013 Elsevier Inc. 1313
(legend on next page)
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Compound 15 significantly decreased expression of Dex-
induced genes, confirming that Dex activity in the LREX0
model is GR dependent (Figure S4C). Lastly, small interfering
RNA (siRNA) experiments targeting AR confirmed that AR
is not necessary for Dex-mediated gene activation (Figure S4D).
Collectively, these experiments demonstrate that GR is able
to drive expression of certain AR target genes independent
of AR.
AR and GR Have Overlapping Transcriptomes and
Cistromes
To explore AR andGR transcriptomes in an unbiased fashion, we
performed expression profiling after short-term treatment of
LREX0 cells with DHT or Dex in the presence or absence of enza-
lutamide. AR and GR signatures were respectively defined as all
genes with absolute expression change greater than 1.6-fold
(FDR < 0.05) after 1 nM DHT or 100 nM Dex treatment (Table
S3). Of the 105 AR signature genes and 121 GR signature genes,
52 were common to both lists (Figure 5A). An even larger propor-
tion of AR or GR signature genes (>80%) showed evidence of
regulation by the reciprocal receptor using different thresholds
for expression differences (Table S3). Heatmap analysis of these
genes confirmed significant overlap in DHT- versus Dex-induced
gene expression and showed that Dex-induced gene expression
is not impacted by enzalutamide treatment (Figure 5B). These
findings support the hypothesis that GR activity can bypass
enzalutamide-mediated AR inhibition by regulating a distinct
but significantly overlapping transcriptome.
We next addressed the question of whether transcriptomes
of enzalutamide-resistant tumors are more likely to be explained
by AR- or GR-driven gene expression using gene set enrichment
analysis (GSEA). To define gene sets that distinguish AR and GR
activity, expression of AR and GR signature genes was first eval-
uated byGSEA in the DHT- andDex-treated samples fromwhich
they were derived. As expected, GR signature genes were
enriched in the Dex-treated samples, and AR signature genes
were enriched with DHT treatment (Figure 5C). Because several
of the genes did not distinguish AR and GR status due to their
overlapping transcriptional activities, we refined the lists into
AR selective genes (defined as the AR-induced signature genes
that were also more highly expressed in DHT-treated samples
relative to Dex treated samples, n = 39) and GR selective genes
(defined as the converse, n = 67) (Table S3). GSEA analysis of
these selective gene lists revealed that GR selective genes
were strongly enriched in the enzalutamide-resistant LREX0
tumors, whereas AR selective genes were strongly enriched in
the control tumors (Figure 5D). These data provide compelling,
unbiased evidence that drug resistance is associatedwith a tran-
sition from AR- to GR-driven transcriptional activity.Figure 4. Variable Expression of AR Target Genes in LREX0 In Vivo and
(A) Normalized expression array signal (Illumina HT-12) of a suite of 74 AR target g
Genes are ranked by degree of restoration of expression in resistant tissue ([Res
treatment through time of harvest.
(B) Fractional restoration values of each of the 74 AR targets in LREX0 xenografts (
(C) GR mRNA in resistant tissues used in (B).
(D) Relative Expression ± SEM of AR target genes in the LREX0 cell line in stero
Enzalutamide, 10 mM; V, Vehicle.
See also Figures S3 and S4.One prediction of this model is that GR should occupy a
substantial portion of AR binding sites in drug-resistant cells.
To address this question, we conducted chromatin immuno-
precipitation sequencing (ChIP-seq) experiments to define AR
and GR DNA binding sites in LREX0 cells after DHT and Dex
treatment, respectively. Of note, 52% of the AR binding sites
identified after DHT treatment were bound by GR after Dex
treatment (Figure 5E). We examined the remaining 48% of AR
peaks more closely to be sure that these peaks were not scored
as GR negative simply because they fell just below the threshold
set by our peak calling parameters.Whenwe plotted the average
AR and GR signal as a measure of the relative strength of AR
and GR peaks, we found little evidence of GR binding at the
AR unique sites (Figure S5A), confirming that these peaks were
indeed unique to AR. Next we conducted motif analysis to
explore potential differences between AR/GR overlap versus
AR unique sites. The core ARE/GRE consensus sequence was
present in both groups (66% and 68% of peaks), but AR/GR
overlap peaks were relatively enriched for the FoxA motif (64%
versus 45% of peaks; p = 2.2 3 1016) (Figure 5E). Similar anal-
ysis of the GR cistrome defined GR unique and AR/GR overlap
peaks and revealed that a higher proportion of GR binding sites
were unique to GR. Interestingly, GR unique peaks were highly
enriched for the FoxA motif (Figure 5F), whereas the classic
ARE/GRE was not reported by the motif discovery algorithm
(MEME) and was found only 25% of the time.
Although these cistrome studies provide evidence of sub-
stantial overlap between AR and GR binding sites in enza-
luamide-resistant cells, several lines of evidence indicate that
the transcriptional differences in DHT- versus Dex-induced
gene expression cannot be explained solely by DNA binding.
For example, ChIP RT-qPCR experiments showed significant
AR and GR DNA binding at genes induced by both receptors
(SGK1, FKBP5, PSA) but also at genes such as NDRG1 that
are transcriptionally activated by DHT, but not Dex (Figure S5B).
Integrative ChIP-seq and transcriptome analysis provided
further evidence that DNA binding is not sufficient to determine
transcriptional competence. Of the 56 AR signature genes found
to have an AR binding peak, 49 showed at least some tran-
scriptional regulation by GR (1.2-fold expression change, p <
0.05). 38 of these 49 GR regulated genes (78%) had an over-
lapping AR/GR binding peak, confirming substantial overlap
at coregulated genes. But GR peaks were also found in three
of the seven AR targets genes (43%) with no apparent GR tran-
scriptional regulation (Figure S5C). Others have reported evi-
dence of allosteric regulation of hormone receptor complexes
by specific DNA sequences independent of binding affinity
(Meijsing et al., 2009), a phenomenon that may also be relevant
here.after Glucocorticoid Treatment In Vitro
enes in control (n = 10), 4 day (n = 8), and LREX0 (n = 8, right) xenograft tumors.
-4 day]/[Control-4 day]). All resistant tissues were continued on antiandrogen
n = 8) or resistant tissues from the validation cohort (n = 12, see also Figure S3).
id depleted media after 8 hr of treatment with the indicated agonists in vitro.
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Figure 5. Comparative AR and GR Transcriptome and Cistrome Analysis in LREX0
(A) Venn diagram of AR and GR signature gene lists. AR or GR signatures were defined as all genes showing >1.6 (or <1.6)-fold change (FDR < 0.05) after 8 hr of
addition of DHT (1 nM) or Dex (100 nM) to charcoal-stripped media, respectively.
(B)Heatmapdepictionof expression changesofARsignature genes (left) orGRsignature genes (right) associatedwith the indicated treatment. Enzalutamide, 10mM.
(C) Expression of AR- or GR-induced signature genes (as defined in A) were compared in DHT (1nM) or Dex (100 nM)-treated samples. GR signature genes that
also had higher expression in Dex samples (>1.1-fold, FDR < 0.05) were designated as GR selective (n = 67), and AR signature genes that showed higher
expression in DHT samples (>1.1-fold, FDR < 0.05) were designated as AR selective (n = 39).
(legend continued on next page)
1316 Cell 155, 1309–1322, December 5, 2013 ª2013 Elsevier Inc.
Figure 6. GR Activity Is Sufficient to Confer
Enzalutamide Resistance in VCaP
For all panels: VCaP cells do not tolerate charcoal-
stripped media and were cultured in standard
culture conditions (fetal bovine serum with
endogenous hormones). Enz, 10 mM;Dex, 100 nM;
and CMP 15, 1 mM.
(A) Western blot analysis of prostate cancer cell
lines.
(B–D) Cell viability assessed by CellTiter-Glo
(Promega) assay and normalized to day 1 value
after indicated treatments ± SEM.
(E) Confirmation of GR knockdown bywestern blot
after infection with GR targeting shRNA.
(F) Apoptosis as assessed by cPARP western blot
after 3 days of indicated treatment.
(G) A suite of AR targets relevant to VCaP was
defined (see Experimental Procedures) and
normalized expression of each gene after 24 hr of
indicated drug treatments is depicted by heatmap
and ranked by degree of induction with Dex.
(H) Expression of the top two genes from (B)
(KLK2 and FKBP5) after 24 hr of indicated treat-
ments ± SEM.
See also Figure S6.Activation of GR by Dexamethasone Is Sufficient to
Confer Enzalutamide Resistance
Whereas LNCaP/AR cells acquire GR expression after pro-
longed exposure to enzalutamide, some prostate cancer cell
lines derived from CRPC patients (DU145, PC3, and VCaP) ex-
press endogenous GR (Figure 6A). DU145 and PC3 cells are
AR negative and, hence, are resistant to enzalutamide, but(D) Expression of AR- and GR-selective genes in LREX0 and control tumors in vivo compared by GSEA.
(E) AR cistrome defined by ARChIP-seq after DHT (1 nM) treatment of LREX0 in vitro in charcoal-strippedmedia
peaks found byGRChIP-seq after Dex (100 nm) treatment of LREX0 in vitro are shown in pie graph. Top binding
indicated below.
(F) GR cistrome defined by GR ChIP-seq after Dex treatment of LREX0 in vitro in charcoal-stripped media. Per
by AR ChIP-seq after DHT (1 nM) treatment of LREX0 in vitro are shown in the pie graph. Top binding motifs in
below.
See also Figure S5.
Cell 155, 1309–1322, DVCaP cells are enzalutamide sensitive
in vitro (Tran et al., 2009). IHC analysis
showed diffuse, primarily cytoplasmic
GR expression under standard culture
conditions that lack glucocorticoid sup-
plementation (Figure S6A). To test
whether GR activation by addition of glu-
cocorticoids impacts antiandrogen
sensitivity, we treated VCaP cells with
enzalutamide in the presence or absence
of Dex. Enzalutamide inhibited growth as
expected, but cotreatment with Dex
reversed this growth inhibition (Figure 6B).
Additional studies with the GR antago-
nist, compound 15, or with GR shRNA
restored enzalutamide sensitivity and
provided pharmacologic and genetic evi-
dence that GR confers resistance (Fig-ures 6C–6E). Of note, GR knockdown (which inhibits GR more
completely than compound 15, which has mixed agonist/antag-
onist properties [Wang et al., 2006]) augmented the activity of
enzalutamide even in the absence of Dex (Figures 6D and 6F),
suggesting that even the weak basal GR activity seen under
our standard culture conditions can confer relative resistance
to enzalutamide. This result also suggests that a pure GR. Percent of AR defined peaks that overlapwith GR
motifs in AR-unique and AR/GR overlap peaks are
cent of GR peaks that overlap with AR peaks found
GR-unique and AR/GR overlap peaks are indicated
ecember 5, 2013 ª2013 Elsevier Inc. 1317
(legend on next page)
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antagonist could enhance the activity of enzalutamide in pros-
tate cancers coexpressing GR and AR.
To determine whether Dex activates a subset of AR target
genes in VCaP (as we observed in the LREX0 model), we derived
a list of AR target genes in VCaP cells exposed to DHT and asked
whether Dex could modulate these same AR target genes in the
presence of enzalutamide. Dex restored expression of some
targets (KLK2, FKBP5, HOMER2, and SLC45A3), but not others
(DHCR24, SLC2A3, TRPM8, and TMEM79), analogous to the
uneven restoration we observed in the LNCaP/AR model (Fig-
ure 6G). Dex also induced expression of the clinical biomarker
PSA in these cells, further supporting the hypothesis that GR
can drive PSA progression in enzalutamide-resistant patients
(Figures S6B and S6C). To confirm that Dex activated genes
via the glucocorticoid receptor, we evaluated the effect of com-
pound 15 on Dex-induced transcriptional activity. As expected,
compound 15 reduced Dex induction of the GR targets KLK2
and FKBP5 (Figure 6H). Similarly, GR knockdown prevented
Dex-mediated induction of target genes (Figure S6C). As in the
LREX0 system (Table S3), the vast majority of genes robustly
regulated by GR activation in VCaP cells were also regulated
by AR activation with DHT (Table S4). Others have recently
shown substantial overlap in the AR and GR cistromes in VCAP
as well (Sahu et al., 2013). These findings extend our hypothesis
that GR promotes enzalutamide resistance largely by replacing
AR activity at a subset of genes to a second model system.
A Subset of Prostate Cancer Is Primed for GR Induction
in the Setting of AR Inhibition
In considering potential mechanisms for increased GR expres-
sion in drug-resistant tumors, we noted several observations
that suggested two distinct models. First, flow cytometry anal-
ysis of LNCaP/AR and CS1 cells revealed GR expression in a
rare subset of cells (Figure 1E), raising the possibility that these
cells clonally expand under the selective pressure of antiandro-
gen therapy. Consistent with this model, we observed rare GR-
positive cells in a tissue microarray analysis of 59 untreated
primary prostate cancers (Table S5). However, we also observed
a modest (2-fold) but significant increase in GR mRNA levels in
LNCaP/AR xenografts after only 4 days of antiandrogen treat-
ment, which is reminiscent of an older report of increased GR
expression in normal ventral rat prostate after castration (Davies
and Rushmere, 1990). These findings suggest a secondmodel of
adaptive resistance whereby AR inhibition causes an increase in
GR levels due to loss of AR-mediated negative feedback.
To investigate the relationship between AR activity and GR
expression, we first asked whether the high level of GR expres-Figure 7. Resistant Cells Are Primed for GR Induction upon AR Inhibit
(A) GRmRNA in LREX0 xenografts. Tumors were injected into castratedmice and i
mice were then continued on 10 mg/kg enzalutamide (n = 10 tumors) or discont
(B) LREX0 are maintained in vitro in the presence of enzalutamide 1 mM. GR mRNA
standard fetal bovine serum containing media without enzalutamide.
(C) GR mRNA in LREX0 cultured in charcoal-stripped media for 48 hr and then tr
(D) AR ChIP-qPCR with LREX0 cultured in charcoal-stripped media and then trea
(E) Intracellular GR flow cytometric analysis of indicated cells at indicated times
(F) Plotted median fluorescence (minus background) values from (E) and Figure S
(G) Model of GR induction in resistant tissues.
See also Figure S7.sion in LREX0 tumors is maintained after discontinuation of
enzalutamide. Remarkably, GR mRNA levels dropped by 5-
fold 8 days after treatment discontinuation (Figure 7A). Because
enzalutamide has a prolonged half-life in mice (Tran et al., 2009),
it is difficult to make definitive conclusions about negative
feedback loops using in vivo models. Therefore, we conducted
similar enzalutamide withdrawal experiments in LREX0 cells
cultured in vitro. GRmRNA levels dropped as early as 1 day after
discontinuation and continued to decline throughout the 23 days
of the experiment (Figure 7B). Additional experiments with LREX0
cells using earlier time points in charcoal-strippedmedia showed
reduced GR mRNA levels after only 8 hr of DHT exposure, and
this reduction was reversed by cotreatment with enzalutamide
(Figure 7C). This reduction correlated precisely with the
recruitment of an AR binding peak in an intronic enhancer of
GR identified by ChIP, suggesting that AR directly represses
GR expression in these cells (Figure 7D).
To determine whether the loss of GR expression upon enzalu-
tamide withdrawal occurs across the entire cell population or is
restricted to a subset of cells, we conducted flow cytometry
experiments in which a shift in median signal intensity can be
used to identify expression changes in the bulk cell population.
(Expression changes limited to a minority subpopulation would
not affect the median and would instead be identified as a tail
population by histogram plot.) We observed an exponential
decay in median GR protein signal (half-life 7.6 days) (Figure 7E,
top row, and Figure 7F), confirming that the loss in GR expres-
sion occurs across the entire LREX0 cell population. Extension
of this experiment to later time points (17 weeks) revealed a
plateau in loss of GR expression by 7 weeks (Figure S7A).
Next, we conducted the reciprocal experiment of re-exposure
of LREX0 cells to enzalutamide followingGRdownregulation after
prolonged enzalutamide withdrawal (LREX0off). GR expression
was regained with induction kinetics essentially reciprocating
the rate of decay previously seen with removal of drug (doubling
time 6.8 days), establishing that the resistant line remained
poised for GR induction in the setting of AR inhibition (Figures
7E and 7F). Consistent with the timescale, continued drug
exposure for 7 weeks was associated with a clear shift in GR
expression in essentially all cells (Figure S7A).
We next determined whether AR inhibition is sufficient to
induce GR expression in LNCaP/AR or CS1 cells that had not
previously been exposed to enzalutamide. In contrast to LREX0,
there was no change in median expression intensity in CS1 or
LnCaP/AR over the 4week experiment, indicating that most cells
do not turn on GR expression simply as a consequence of AR
inhibition (Figures 7E, 7F, and S7C). However, the area underion
mmediately treated with 10mg/kg enzalutamide (n = 20) for 7 weeks. Half of the
inued for 8 days (n = 10 tumors).
was assessed in LREX0 cell line after passage for indicated number of days in
eated for 8 hr with vehicle or DHT with or without 10 mM enzalutamide.
ted for 1 hr with DHT (1 nM) or Dex (100 nM) at an intronic enhancer site ± SD.
points. AUC, area under curve. Enzalutamide, 1 mM.
7C. For both LREX plots, R2 values for nonlinear regression analysis is >0.98.
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the GR staining population did increase. Given the weak anti-
proliferative effect of enzalutamide in vitro (Figure S7B), we
conclude that this increase in GR expression is most likely
explained by loss of AR-mediated negative feedback rather
than by clonal expansion. Together, these findings support a
model in which a subset of prostate cancer cells are ‘‘primed’’
for GR induction in the context of AR inhibition through an adap-
tive resistance mechanism (via AR-mediated negative feed-
back). We postulate that these cells then clonally expand under
the selective pressure of AR blockade, eventually emerging as
drug-resistant tumors whose expression profiles may resemble
those of AR-driven tumors but are driven by GR (Figure 7G).
DISCUSSION
Following the recent approvals of the next-generation AR
pathway inhibitors abiraterone and enzalutamide, the treatment
of metastatic prostate cancer has evolved to a two-stage
process. Initially, patients receive conventional androgen depri-
vation therapy, typically with a gonadotropin-releasing hormone
agonist that lowers testosterone (castration), often in conjunction
with an antiandrogen such as bicalutamide. Preclinical and clin-
ical studies have conclusively demonstrated that acquired resis-
tance to conventional androgen deprivation therapy is caused by
restoration of AR pathway activation, primarily due to increased
AR expression. These discoveries provided the rationale for the
development of next-generation AR therapies.
Here, we demonstrate that acquired resistance to at least one
of these new next-generation therapies, enzalutamide, can
occur via a different mechanism—increased expression of GR.
The evidence for GR-driven resistance emerged from two inde-
pendent preclinical models (LNCaP/AR and VCaP) and was
supported by correlative data showing increased GR expression
in patients with enzalutamide resistance. Consistent with our
mechanistic studies showing that GR can function indepen-
dently of AR, increased GR expression was also associated
with ARN-509 resistance, potentially forecasting a general
mechanism of resistance to antiandrogens. Whether increased
GR expression plays a role in abiraterone resistance remains
to be determined. Unlike enzalutamide and ARN-509, abirater-
one impairs AR signaling by lowering residual systemic and intra-
tumoral androgen levels, and preclinical evidence suggests that
abiraterone resistance may be associated with increased AR
expression (Mostaghel et al., 2011). We speculate that tumors
can efficiently overcome the ligand deficiency conferred by tradi-
tional androgen-deprivation therapy or abiraterone by simply
elevating AR levels, whereas the increased selection pressure
conferred by second-generation antiandrogens requires an
alternative strategy such as GR bypass or AR mutation (Balbas
et al., 2013; Joseph et al., 2013; Korpal et al., 2013).
Comparative AR and GR transcriptome studies supported a
model whereby GR bypasses enzalutamide-mediated AR
blockade without the need for any restored AR function. This
model is further supported by ChIP-seq analyses showing that
GR can bind to just over half of all AR binding sites in enzaluta-
mide-resistant cells. Importantly, GR occupied a large number
of sites that are not bound by AR, raising the possibility of a
distinct GR transcriptional program that could contribute to1320 Cell 155, 1309–1322, December 5, 2013 ª2013 Elsevier Inc.resistance. However, our transcriptome analysis found that a
large majority of genes robustly regulated by GR were also regu-
lated by AR. Notably, several canonical AR targets genes,
including KLK3 and TMPRSS2, show regulation by GR (Table
S3). For these reasons, we believe that the antiandrogen resis-
tance conferred by GR is most likely mediated by one or more
of the unevenly restored AR target genes rather than a distinct
set of ‘‘GR only’’ target genes. It will be of interest to explore
whether just one or a small number of downstream targets are
responsible for resistance and also why GR fails to activate tran-
scription at the vast majority of the ‘‘GR unique’’ binding sites.
We postulate that variables such as chromatin context, cofac-
tors, and other signaling events may be important.
The GR bypass model of AR pathway blockade reported here
is reminiscent of recent reports that kinase inhibitor blockade in
various cancers can be overcome by upregulation of other
kinases and/or their ligands (Engelman et al., 2007; Johannessen
et al., 2010; Straussman et al., 2012; Wilson et al., 2012). To our
knowledge, our observation is the first example of nuclear recep-
tor bypass as a mechanism of acquired resistance to nuclear
receptor blockade. In the case of kinase inhibitors, bypass is
just one of many potential resistance mechanisms that also in-
cludes direct mutation of the kinase target and lineage switching
to histologically distinct phenotypes that no longer require the
drug target for survival (Sequist et al., 2011). We believe the
same may be true here based on the fact that a subset of
drug-resistant LNCaP/AR tumors had minimal GR expression,
raising the possibility of other resistance drivers. For example,
one of these low GR tumors contained the F876L AR mutation
that converts both ARN-509 and enzalutamide to agonists and
is associated with clinical resistance (Balbas et al., 2013; Joseph
et al., 2013; Korpal et al., 2013). A second low GR tumor
expressed high levels of N-cadherin (Table S1C), which can
confer AR independence by morphological conversion to a tu-
mor with mesenchymal features (Tanaka et al., 2010).
Expression of GR in antiandrogen-resistant prostate tumors
appears to occur by a mechanism that includes features of
adaptive resistance (via AR-mediated negative feedback of GR
expression), as well as clonal selection. Our data showed that
AR inhibition induced strong GR expression in drug-resistant
prostate cancer cells, as well as in a subset of drug-naive cells
that are somehow ‘‘primed’’ to respond. The molecular basis
for this ‘‘primed’’ state remains to be defined but, based on the
reversibility of GR expression in the presence or absence of
AR inhibition, is likely to involve an epigenetic mechanism.
Knowledge of baseline tumor GR expression in patients, as
well as the ‘‘primed’’ state of these tumor cells, could have clin-
ical relevance as a treatment response biomarker. We already
have evidence that baseline GR expression may predict for a
poor clinical outcome despite a limited clinical data set and,
based on the increase in GR expression in some patients after
8 weeks of treatment, that the ‘‘priming’’ phenomenon observed
in our models may also be relevant in patients.
Whatever the precise mechanism regulating GR expression,
one immediate implication is that corticosteroid therapy could
be detrimental to prostate cancer patients in certain clinical
contexts. Corticosteroids are currently administered routinely
with both docetaxel and abiraterone to prevent side effects
from each of these therapies. Our data suggest that corticoste-
roids might promote tumor progression in men whose tumors
express GR. Indeed, reanalysis of the phase 3 clinical trial
AFFIRM that demonstrated a survival benefit with enzalutamide
treatment found that men receiving corticosteroids had a signif-
icantly worse survival than those who did not (Scher et al., 2012,
ESMO, abstract; Scher et al., 2012). It is worth noting that corti-
costeroids can also confer clinical benefit in CRPC, an effect
attributed to feedback suppression of pituitary ACTH production
and resultant decrease in adrenal androgen production (Tan-
nock et al., 1989). This duality of potential glucocorticoid effects
should prompt a reexamination of the appropriate clinical
context for corticosteroid therapy.
Our findings also suggest that combined inhibition of both GR
and AR could prolong the duration of response with next-
generation AR antagonists. Clinical studies of the GR antagonist
mefipristone in patients with excess glucocorticoid production
(Cushing syndrome) demonstrate that GR can be inhibited in
humans with an acceptable risk-benefit profile (Fleseriu et al.,
2012). Unfortunately, both mefipristone and a related GR antag-
onist ORG34517 activate AR target gene expression, likely by
direct AR agonism because mefipristone binds and activates
AR (Klokk et al., 2007). The ability of compound 15 to overcome
GR-driven resistance should stimulate further efforts to optimize
GR-specific antagonists that lack ‘‘off target’’ AR effects for use
in preventing or overcoming enzalutamide resistance.
EXPERIMENTAL PROCEDURES
Bone Marrow Evaluation
Patients were treated with enzalutamide 160 mg daily. Bone marrow biopsy
and aspirate (5 ml) were performed before treatment and at week 8. The
bone marrow specimens were obtained by transiliac biopsy, and samples
were processed according to standard MD Anderson Cancer Center decalci-
fication and fixation procedures. After pathologic evaluation, samples were
stored in the MD Anderson Cancer Center Prostate Cancer Tissue Bank.
Imaging studies were performed at the time of suspected prostate cancer
progression or at the treating physician’s discretion but generally were not per-
formed prior to 12weeks posttreatment initiation. Therapywas discontinued at
the treating physician’s discretion in patients exhibiting progression. Retro-
spective analysis for GR was performed by IHC on 3.5 mm formalin-fixed,
paraffin-embedded bone marrow biopsy sections with anti-GR at a dilution
of 1:200 (BD Transduction Laboratories 611227). A Dako autostainer and stan-
dard 3,3-diaminobenzidine were used. GR expression was assessed in a
blinded fashion by two pathologists scoring at least 100 tumor cells per spec-
imen. Plotted are either data from all specimens or only from patients with us-
able material at baseline and 8 weeks.
AR Target Gene List Derivation
The 74 AR target gene list utilized for evaluation of AR pathway status in the
LnCaP/AR model includes all genes that showed at least a 1.6-fold change
(FDR < 0.05) when comparing control and 4 day treated xenografts and that
were also found to have an AR binding peak by ChIP-seq analysis of
LNCaP/AR in vitro (L.C., D.Z., and C.L.S., unpublished data). The VCaP AR
target gene list includes all genes that showed reciprocal expression change
with 24 hr DHT (.1 nM) or enzalutamide (10 mM) of at least 1.4-fold (p < 0.05)
(Illumina HT-12) and were also found to have an AR binding peak by ChIP-
seq analysis of VCaP (L.C., D.Z., and C.L.S., unpublished data).
AR/GR Signature Analysis and GSEA
AR and GR signature genes were defined as all genes showing >1.6-fold
(FDR < 0.05) expression change with either 1 nM DHT or 100 nM Dex treat-ment, respectively, of LREX0 cells for 8 hr in charcoal-stripped media. For
GSEA, signature genes induced by either DHT or Dex treatment were used.
GR selective genes showed at least 1.1-fold higher expression in Dex-treated
samples compared to DHT-treated samples (FDR < 0.05). AR selective genes
showed at least a 1.1-fold higher expression in DHT-treated samples
compared to Dex-treated samples (FDR < 0.05).
Statistics
Microarray data analysis and comparisons were performed with Partek Soft-
ware. All RT-qPCR comparisons are by two-sided t test. Xenograft volumes
and GR IHC of clinical specimens are compared by one-sided Mann-Whitney
test. In vitro growth comparisons are by two-sided t test. GSEA statistical anal-
ysis was carried out with publicly available software from the Broad Institute
(http://www.broadinstitute.org/gsea/index.jsp). In all figures, *p = < 0.05,
**p = < 0.01, ***p = < 0.001, and ****p = < 0.0001.
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